Literature DB >> 29593287

Cardioprotection: SGLT2 blockers in T2DM.

Caroline Barranco.   

Abstract

Entities:  

Year:  2018        PMID： 29593287     DOI： 10.1038/nrcardio.2018.35

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.

Authors:  Mikhail Kosiborod; Carolyn S P Lam; Shun Kohsaka; Dae Jung Kim; Avraham Karasik; Jonathan Shaw; Navdeep Tangri; Su-Yen Goh; Marcus Thuresson; Hungta Chen; Filip Surmont; Niklas Hammar; Peter Fenici
Journal:  J Am Coll Cardiol       Date:  2018-03-11       Impact factor: 24.094

2.  Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Karin Rådholm; Gemma Figtree; Vlado Perkovic; Scott D Solomon; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Terrance D Barrett; Wayne Shaw; Mehul Desai; David R Matthews; Bruce Neal
Journal:  Circulation       Date:  2018-07-31       Impact factor: 29.690
  2 in total
  1 in total

Review 1.  Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents.

Authors:  Bilin Xu; Zhiliang Li; Ting Zeng; Jianfeng Zhan; Shuzhen Wang; Chi-Tang Ho; Shiming Li
Journal:  Molecules       Date:  2022-03-28       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.